Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Equity Average (2020 - 2025)

Vivos Therapeutics has reported Equity Average over the past 6 years, most recently at $521000.0 for Q4 2025.

  • Quarterly Equity Average fell 93.33% to $521000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $521000.0 through Dec 2025, down 93.33% year-over-year, with the annual reading at $3.2 million for FY2025, 22.73% down from the prior year.
  • Equity Average was $521000.0 for Q4 2025 at Vivos Therapeutics, down from $3.6 million in the prior quarter.
  • Over five years, Equity Average peaked at $34.5 million in Q3 2021 and troughed at $228500.0 in Q4 2023.
  • The 5-year median for Equity Average is $6.6 million (2024), against an average of $10.5 million.
  • Year-over-year, Equity Average plummeted 96.88% in 2023 and then skyrocketed 3317.72% in 2024.
  • A 5-year view of Equity Average shows it stood at $29.0 million in 2021, then tumbled by 74.73% to $7.3 million in 2022, then plummeted by 96.88% to $228500.0 in 2023, then skyrocketed by 3317.72% to $7.8 million in 2024, then crashed by 93.33% to $521000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Equity Average are $521000.0 (Q4 2025), $3.6 million (Q3 2025), and $4.5 million (Q2 2025).